The latest price target for BioAtla (NASDAQ:BCAB) was reported by JMP Securities on September 16, 2024. The analyst firm set a price target for $5.00 expecting BCAB to rise to within 12 months (a possible 201.20% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for BioAtla (NASDAQ:BCAB) was provided by JMP Securities, and BioAtla reiterated their market outperform rating.

There is no last upgrade for BioAtla

The last downgrade for BioAtla Inc happened on May 5, 2022 when Credit Suisse changed their price target from $35 to $5 for BioAtla Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioAtla, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioAtla was filed on September 16, 2024 so you should expect the next rating to be made available sometime around September 16, 2025.

While ratings are subjective and will change, the latest BioAtla (BCAB) rating was a reiterated with a price target of $5.00 to $5.00. The current price BioAtla (BCAB) is trading at is $1.66, which is out of the analyst’s predicted range.